Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.

ABSTRACT:

Background

Recent single-cell studies indicated that IL-17-producing T cells (T17) have diverse subsets expressing IL-17A, IL-17F, or a combination in human psoriasis skin. However, it is unknown how T17 subsets are differently regulated by IL-23 versus IL-17A blockade.

Objective

We sought to investigate how systemic monoclonal antibody injections blocking IL-23 versus IL-17A differently modify immune cell transcriptomes in human psoriasis skin.

Methods

We analyzed a total of 93 human skin single-cell libraries, including 42 psoriasis pretreatment lesional skin, 25 psoriasis pretreatment nonlesional skin, 12 psoriasis posttreatment after IL-23 inhibition, 4 psoriasis posttreatment after IL-17A inhibition, and 10 control skin samples.

Clinicaltrials

gov NCT04630

SUBMITTER: Kim J 

PROVIDER: S-EPMC12145251 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature